What are the potential side effects of a glucagon-like peptide‑1 (GLP‑1) receptor agonist used for ophthalmic (eye) applications?

GLP-1 Agonists and Ophthalmic Side Effects

The most clinically significant ophthalmic concern with GLP-1 receptor agonists is diabetic retinopathy complications, particularly in patients with pre-existing retinopathy who experience rapid HbA1c reduction, though the overall risk appears modest and should not preclude use in most patients given the substantial cardiovascular and mortality benefits. 1

Primary Ophthalmic Concerns

Diabetic Retinopathy Complications

Diabetic retinopathy complications were specifically reported with injectable semaglutide, though it remains unclear whether this represents a direct drug effect or results from rapid improvement in blood glucose control. 1 The evidence shows:

• The SUSTAIN-6 trial documented increased diabetic retinopathy complications with semaglutide, particularly in patients with baseline retinopathy experiencing rapid HbA1c reduction 2
• This appears to represent "early worsening" phenomenon rather than true disease progression 2
• The REWIND and LEADER trials with other GLP-1 RAs showed no significant increase in diabetic retinopathy risk, suggesting variability among specific agents 2
• Recent meta-analyses of observational studies found no increased risk of retinopathy development or progression overall (HR 0.96-0.97) 3

Clinical Action Required: Patients should undergo appropriate guideline-recommended eye examinations before starting GLP-1 RA therapy if not completed within the last 12 months 1. This is particularly critical for patients with known diabetic retinopathy or those likely to experience rapid glycemic improvement.

Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Recent pharmacovigilance data has raised concerns about NAION risk, particularly with semaglutide:

• The European Medicines Agency has classified NAION as a very rare adverse effect of GLP-1 RAs 2
• Pharmacoepidemiologic studies have implicated semaglutide specifically 2
• However, large meta-analyses of randomized controlled trials found no significant association (OR 1.50,95% CI 0.49-4.63) 4
• Observational studies show conflicting results, with some suggesting increased risk while others show no difference (RR 1.01,95% CI 0.62-1.64) 3

The mechanism remains unclear, and the absolute risk appears very low 5.

Common Non-Vision-Threatening Side Effects

The most frequent adverse effects are gastrointestinal symptoms occurring in approximately 25% of patients for nausea, and up to 10% for vomiting and diarrhea 6. These are:

• Typically mild and self-limiting 7, 8
• Occur mainly during initial treatment and diminish over time 7
• Lead to discontinuation in fewer than 5% of patients 8
• Can be mitigated by slow titration, eating smaller meals, avoiding overeating, and stopping when feeling full 1, 6

Other common adverse effects include:

• Injection site reactions 1
• Headache, weakness, or dizziness 1
• Weight loss (typically 5-10% on average, which is often therapeutic) 6

Serious Adverse Effects Requiring Monitoring

Pancreatitis

• Despite postmarketing reports, a causal relationship has not been demonstrated 8
• Discontinue immediately if pancreatitis is suspected (severe abdominal pain with or without nausea/vomiting) and do not restart if confirmed 1, 8, 1, 8, 6

Gallbladder/Biliary Disease

• All GLP-1 RAs increase risk of gallbladder or biliary disease 6
• Tirzepatide specifically noted to increase this risk 6

Hypoglycemia

• Risk increased when combined with insulin, sulfonylureas, or glinides 1
• Consider discontinuing sulfonylurea or glinide and reducing total daily insulin dose by up to 20% when initiating GLP-1 RA 1
• Monitor glucose closely for first 4 weeks 1

Potential Protective Effects

Emerging evidence suggests possible protective associations with certain ocular conditions:

• Reduced risk of neovascular age-related macular degeneration in some studies 2, 9
• Protective effects against glaucoma (HR 0.84,95% CI 0.71-1.00) 5, 3
• Reduced dry eye disease 5
• Decreased intracranial pressure in idiopathic intracranial hypertension 5

These findings remain inconsistent across studies and require further validation 2, 10.

Absolute Contraindications

• Personal or family history of medullary thyroid cancer 1, 6
• Personal or family history of multiple endocrine neoplasia type 2 (MEN2) 1, 6
• History of serious hypersensitivity reaction to the drug 1
• Pregnancy or breastfeeding 1
• Severe renal impairment or end-stage renal failure (for exenatide and lixisenatide specifically) 1

Clinical Recommendations

Do not avoid GLP-1 RAs based solely on ophthalmic concerns given their proven cardiovascular and mortality benefits (HR 0.88 for all-cause mortality) 8. The approach should be:

1. Baseline assessment: Ensure eye examination within 12 months before initiation, especially if diabetic retinopathy present 1

2. High-risk patients requiring closer monitoring:

   • Pre-existing diabetic retinopathy
   • Anticipated rapid HbA1c reduction (>2% decrease expected)
   • History of optic nerve disorders

3. Titration strategy: Start at lowest dose and up-titrate slowly to reduce gastrointestinal symptoms and potentially minimize rapid glycemic shifts 1

4. Avoid in specific situations:

   • Active diabetic gastroparesis 1
   • Active gallbladder disease 1

5. Regular ophthalmologic follow-up for high-risk patients, though routine screening beyond standard diabetes care is not required for most patients 5

The overall evidence from randomized controlled trials involving 83,288 participants over 240,334 patient-years shows no increased risk of composite optic nerve or vision-threatening events (OR 1.20,95% CI 0.73-1.97) 4, supporting their continued use with appropriate monitoring.